1Jorissen RN, Walker F, Pouliot N, et ol. Epidermal growth factor receptor: mechanisms of activation and signalling [J]. Exp Cell Res, 2003, 284(1): 31-53.
2Wu X, Deng Y, Wang G, et al. Combining siRNA at two different sites in the EGFR to suppress its expression, induce apoptosis, and enhance 5-fluorouracil sensitivity of colon cancer cells [J]. J Surg Res, 2007, 138(1): 56-63.
3Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J]. N Engl J Med, 2004, 350(21): 2129-2139.
4Hunter SB, Brat D J, Olson JJ, et al. Alterations in molecular pathways of diffusely infiltrating glial neoplasms: application to tumor classification and anti-tumor therapy [J]. Int J Oncol, 2003, 23(4): 857-869.
9Agosti RM, Leuthold M, Gullick WJ, et al. Expression of the epidermal growth factor receptot in astrocytic tumours is specifically associated with glioblastoma multiforme [J]. Virchows Arch Pathol Anat Histopathol, 1992, 420 (4): 321-325.
10Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D, et al. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy [J]. Clin Cancer Res, 2005, 11(20): 7480-7489.
3Brandes AA, Franceschi E, Tosoni A, et al. Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. Clin Cancer Res, 2008 , 14 (4) : 957-960.
4Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor ( EGFR ) signaling in cancer. Gene, 2006, 366(1) :2-16.
5De Luca A, Carotenuto A, Rachiglio A, et al. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol, 2008, 214 ( 3 ) :559-567.
6Von Pawel J. Gefitinib ( Iressa, ZD 1839 ) : a novel targeted approach for the treatment of solid tumors. Bull Cancer, 2004, 91(5) :E70-76.
7Servidei T, Riccardi A, Mozzetti S, et al. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib. Int J Cancer, 2008, 123(12) :2939-2949.
8Premkumar DR, Arnold B, Pollack IF. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth. Mol Carcinog, 2006, 45(5) :288-301.
4Massarelli E, Herbst RS. Use of novel second-line targeted thera- pies in non-small cell lung cancer [ J ]. Semin Oncol, 2006,33 ( Suppll ) : 9-16.
5Taylor TE,Furnari FB,Cavenee WK.Targeting EGFR for treatment of glioblastoma:molecular basis to overcome resistance[J].Current Cancer Drug Targets,2012,12(3):197-209.
6Voigt M,Braig F,Gothel M,et al.Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab[J].Neoplasia,2012,14(11):1023-1031.
7Solomon MT,Miranda N,Jorrin E,et al.Nimotuzumab in combination with radiotherapy in high grade glioma patients:a single institution experience[J].Cancer Biol Ther,2014,15(5):504-509.
9Yang WB,Xing BZ,Liang H.Comprehensive analysis of temozolomide treatment for patients with glioma[J].Asian Pac J Cancer Prev,2014,15(19):8405-8408.
10Hong J,Peng Y,Liao Y,et al.Nimotuzumab prolongs survival in patients with malignant gliomas:A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab[J].Exp Ther Med,2012,4(1):151-157.
